Autoimmune Acquired Coagulation Factor Deficiencies

Click here for the open-access review of Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost. 2025;51:491-505. doi: 10.1055/s-0044-1787188. Epub 2024 Jun 12. PMID: 38866039. Abstract Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and […]

Comments (0)

Bleeding Disorders

Jul 22 2025

george

Postpartum DIC

Check with your medical library for this review, dated 7-18-25. Wolfovitz A, Brenner B, Solt I. Postpartum disseminated intravascular coagulation: A comprehensive review of pathophysiology, diagnosis, management, and prevention. Semin Thromb Hemost. doi: 10.1055/a-2645-2845. Epub ahead of print. PMID: 40680793. Abstract Disseminated intravascular coagulation (DIC) in the postpartum period is a rare but potentially life-threatening […]

Fibrinolysis

Genetic Study on VWD Variants

Click the JTH May issue abstract link: Friedman RK, Heath AS, Huffman JE, et al; National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) Consortium; TOPMed Hematology & Hemostasis Working Group; VA Million Veteran Program; Blangero J, Fornage M, Kooperberg C, et al. Genetic study of von Willebrand factor antigen levels ≤ […]

Bleeding Disorders

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]

Bleeding Disorders

July 2025 Quick Question: Hemophilia Therapeutics

At the June 21–25 ISTH meeting in Washington, DC, we heard several quality presentations describing the new hemophilia treatment materials, including updated EHL concentrates plus the bypassing, rebalancing, and gene transfer therapies. In follow-up, our July 2025 Quick Question asks you to select the choice that represents the recently approved rebalancing therapies. Please make your […]

Bleeding Disorders

Differential Discussion: Hemophilia Part 2

On June 6, 2025, Malissa Norfolk and Dave Cabral posted George’s audio PowerPoint, “Have We Cured Hemophilia, Part 1?.” On June 25, Malissa and Dave posted “Have We Cured Hemophilia, Part 2?” Each video is 30″ long. Please feel free to watch and comment below.

Bleeding Disorders

DIC Update

On Monday, June 23, Ecaterina (Katy) Scarlatescu, MD, PhD, Department of Anaesthesia and Intensive Care, Fundeni Clinical Institute, University of Medicine and Pharmacy, Bucharest, Romania, chaired a plenary session of panelists at the ISTH annual meeting in Washington, DC, USA. The panel discussed the 2025 ISTH DIC definition and diagnostic guidelines we reported on June […]

Thrombophilia

Lab Assessment of FVIII Inhibitors

Click here for an open-access article describing the need for factor inhibitor assessment: Favaloro EJ, Curnow J, Pasalic L. Laboratory assessment of factor VIII inhibitors: when is it required? A perspective informed by local practice. J Clin Med. 2024;14:13. doi: 10.3390/jcm14010013. PMID: 39797095; PMCID: PMC11720995. See also our factor inhibitor discussions under the Bleeding Disorders heading.

Bleeding Disorders

When Do We Titer Inhibitors?

Dana Carton asks, “We currently test for factor inhibitors using the clot-based Bethesda titer as well as a chromogenic bovine assay for Hemlibra patients no matter what the factor level. We recently learned that colleagues don’t look for that inhibitor unless the factor level is less than 5%. Is this a common practice, and would […]

Mixing Studies

Video: Have We Cured Hemophilia?

Click here to view my (Geo) video, Have We Cured Hemophilia?, recorded with Professors Malissa Norfolk and David Cabral as part of their series, Differential Discussions. Part One reviews the history of hemophilia management from the time the first antihemophilic factor was produced to 2014 when turned to the extended half-life hemophilia concentrates.

Comments (0)

Bleeding Disorders

Bleeding Disorders

Autoimmune Acquired Coagulation Factor Deficiencies

Postpartum DIC

Genetic Study on VWD Variants

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

July 2025 Quick Question: Hemophilia Therapeutics

Differential Discussion: Hemophilia Part 2

DIC Update

Lab Assessment of FVIII Inhibitors

When Do We Titer Inhibitors?

Video: Have We Cured Hemophilia?

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question